Auxano Advisors LLC Sells 180 Shares of Novo Nordisk A/S (NYSE:NVO)

Auxano Advisors LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,648 shares of the company’s stock after selling 180 shares during the period. Novo Nordisk A/S comprises approximately 1.0% of Auxano Advisors LLC’s investment portfolio, making the stock its 20th biggest holding. Auxano Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,067,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Pacific Center for Financial Services raised its stake in Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after buying an additional 135 shares in the last quarter. Copeland Capital Management LLC grew its holdings in Novo Nordisk A/S by 100.0% in the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after purchasing an additional 141 shares during the last quarter. Bell Investment Advisors Inc grew its holdings in Novo Nordisk A/S by 79.9% in the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. CNB Bank purchased a new position in Novo Nordisk A/S in the fourth quarter worth $26,000. Finally, Citizens National Bank Trust Department grew its holdings in Novo Nordisk A/S by 100.0% in the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock worth $27,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research analyst reports. UBS Group initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Trading Up 1.1 %

NYSE NVO traded up $1.43 during trading hours on Tuesday, reaching $128.31. The company had a trading volume of 7,593,161 shares, compared to its average volume of 4,799,729. The stock has a 50-day moving average of $126.92 and a 200 day moving average of $112.40. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $575.79 billion, a P/E ratio of 47.47, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The company had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a dividend of $0.664 per share. This represents a dividend yield of 0.9%. The ex-dividend date was Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is currently 49.17%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.